• IM/Hematology/Oncology

Edwin M. Posadas, MD, FACP, is Director of the Translational Oncology Program and the Medical Director of the Urologic Oncology Program at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center. He has both clinical and research interests in the treatment of advanced prostate cancer and the biology of cancer metastasis. Posadas is studying the mechanisms through which cancer cells in localized tumors spread to other parts of the body. A protein called FYN, a member of a cancer-causing gene family, was identified in his laboratory as a possible regulator of metastasis and the neuroendocrine phenotype of prostate cancer. Additionally, his laboratory has been studying the role of circulating tumor cells (CTCs) and immune cells (ICs) as biomarkers in prostate and other cancers using novel nanotechnology platforms. His current research interests focus on the most aggressive subtypes of prostate cancer that spread to organs such as the liver and lungs. At Cedars-Sinai, Dr. Posadas is working to define the function of FYN, CTCs, and ICs in prostate cancer, with the goal of applying his basic science findings to the development of new therapies and diagnostic tools that will directly benefit men with advanced prostate cancer. Clinically, he specializes in the use of medical therapies for prostate, kidney, bladder, and testis cancer with an emphasis on integrated, trans-disciplinary care.

View NIH Biographical Sketch

• Medical School: Johns Hopkins School of Medicine, 1998
• Residency: University of Michigan Medical School, 2001
• Fellowship: National Cancer Institute, 2005

View CV

• Cancer Institute (Samuel Oschin Comprehensive Cancer Institute)
• Urologic Oncology
• Cancer
• Medicine